Physician profile
Mackenzie E Young
NPI 1437619301
$6,273.11
in general payments reported to CMS, 2019-2025
52 companies · $670 in 2025
The $670 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $2,379 · 2023: $2,126 · 2024: $924 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,140 · Long Term Medical Supply Or Device Loan: $549 · Education: $30.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,140.27 |
| Long Term Medical Supply Or Device Loan | $549.09 |
| Education | $30.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,500.72 | 2021-2025 | Piqray, Kisqali |
| Pfizer INC. | $492.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $396.77 | 2022-2025 | Tagrisso, Enhertu, Lynparza |
| Amgen INC. | $336.75 | 2022-2024 | Kyprolis |
| Abbvie INC. | $316.37 | 2022-2025 | |
| Celgene Corporation | $276.40 | 2022-2025 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $255.21 | 2021-2025 | Darzalex, Carvykti, Erleada |
| Glaxosmithkline, LLC. | $195.26 | 2022-2024 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $168.14 | 2021-2023 | Keytruda, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $166.42 | 2022-2023 | Alunbrig, Ninlaro |
| Array Biopharma INC | $161.70 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $152.92 | 2022 | |
| Genzyme Corporation | $141.77 | 2021-2024 | |
| Incyte Corporation | $128.07 | 2021-2023 | Monjuvi, Pemazyre |
| Astellas Pharma US INC | $126.70 | 2022-2024 | Padcev |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.